← All trials
NCT04953130
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Nov 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- Jul 7, 2021
- Last posted
- Jul 7, 2021
- Enrollment
- 10400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Institut Català d'OncologiaCollaborator
- University of YorkCollaborator
- University of CambridgeCollaborator
- Karolinska InstituteCollaborator
- Government of TanzaniaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.